Stifel Reiterates Buy Rating on Pliant Therapeutics (PLRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Pliant Therapeutics (PLRX) PT Lowered to $45 at Oppenheimer
August 8, 2024 8:00 AM EDTOppenheimer analyst Jeff Jones lowered the price target on Pliant Therapeutics (NASDAQ: PLRX) to $45.00 (from $48.00) while maintaining a Outperform rating.... More
Pliant Therapeutics, Inc. (PLRX) Misses Q2 EPS by 7c
August 8, 2024 4:08 AM EDTPliant Therapeutics, Inc. (NASDAQ: PLRX) reported Q2 EPS of ($0.92), $0.07 worse than the analyst estimate of ($0.85).
For earnings history and earnings-related data on Pliant Therapeutics, Inc. (PLRX) click here.
... More